Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Arum Kim
Different Mutational Characteristics of the Subsets of EGFR-tyrosine Kinase Inhibitor Sensitizing Mutation-Positive Lung Adenocarcinoma
BMC Cancer
Cancer Research
Oncology
Genetics
Exploring Antecedents & Consequences of Customer Satisfaction With Smartphones: Implications for CRM
Journal of Business & Economics Research (JBER)
Related publications
The Profile of Lung Adenocarcinoma Patients With Positive EGFR Mutation
Green Medical Journal
OA10.01 Patient Preferences for Tyrosine Kinase Inhibitor Treatments for EGFR Mutation Positive Metastatic NSCLC
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
MA27.07 Lung Adenocarcinoma Harboring BRAF G469V Mutation Is Uniquely Sensitive to EGFR Tyrosine Kinase Inhibitors
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Erlotinib in Symptomatic Brain Metastases From a Lung Adenocarcinoma With a Sensitizing EGFR Mutation
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Quantitative Tyrosine Phosphoproteomics of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-Treated Lung Adenocarcinoma Cells Reveals Potential Novel Biomarkers of Therapeutic Response
Molecular and Cellular Proteomics
Biochemistry
Medicine
Analytical Chemistry
Molecular Biology
EGFR Exon 19 Insertions: A New Family of Sensitizing EGFR Mutations in Lung Adenocarcinoma
Clinical Cancer Research
Cancer Research
Oncology
The Association of Acquired T790M Mutation With Clinical Characteristics After Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma
Cancer Research and Treatment
Cancer Research
Oncology
Relationship Between EGFR Mutation and Computed Tomography Characteristics of the Lung in Patients With Lung Adenocarcinoma
Thoracic Cancer
Medicine
Pulmonary
Respiratory Medicine
Oncology
Patients Harboring EGFR Mutation After Primary Resistance to Crizotinib and Response to EGFR-tyrosine Kinase Inhibitor
OncoTargets and Therapy
Oncology
Pharmacology